Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          



A fully-human anti-IL6 antibody coded as FB704A from our own scFv libraries and optimize by affinity maturation technology. FB704A has demonstrated to possess a better efficacy profile than current therapies.

Request for Collaboration
FB704A is a fully human monoclonal antibody against human Interleukin-6 (IL6) and developed by Fountain's proprietary fully-human antibody library and affinity maturation technology.

IL6 is a multifunctional cytokine that regulates pleiotropic roles in immune system, inflammation and hematopoiesis. Therapeutic targeting on the IL6 is therefore considered to be a potential treatment strategy for various diseases, such as Rheumatoid arthritis, other autoimmune and oncological diseases.

FB704A has demonstrated to possess a better efficacy profile than current therapies and is position to IND filing in 2017. We also have a global patent strategy that extends our scopes in different disease indications and combined therapy of FB704A.
1. Rheumatoid arthritis
2. Oncological diseases
Patent Portfolio
1. Taiwan
2. Untied State
People who like this also like
  • Rexis®Rexis®
  • TAH4411 Antiemetic Oral Thin FilmTAH4411 Antiemetic Oral Thin Film
  • Lead optimizationLead optimization
  • CX-5461: RNA Polymerase I (Pol I) Inhibitor ProgramCX-5461: RNA Polymerase I (Pol I) Inhibitor Program
  • Methylation-Specific-PCR (MSP)Methylation-Specific-PCR (MSP)
  • TLC177TLC177
  • PHDC-01PHDC-01
  • BioImage AnalyzerBioImage Analyzer
  • FLISA (IgE/IgG test)FLISA (IgE/IgG test)
  • Taigexyn®  (Nemonoxacin)Taigexyn® (Nemonoxacin)